Glyburide
Approved · FDA / EMAAlso known as 1-((p-(2-(5-chloro-o-anisamido)ethyl)phenyl)sulfonyl)-3-cyclohexylurea, 1-(p-(2-(5-chloro-2-methoxybenzamido)ethyl)benzenesulfonyl)-3-cyclohexylurea, 5-chloro-N-(2-(4-((((cyclohexylamino)carbonyl)amino)sulfonyl)phenyl)ethyl)-2-methoxybenzamide, DiaBeta+9 more
1-((p-(2-(5-chloro-o-anisamido)ethyl)phenyl)sulfonyl)-3-cyclohexylurea, 1-(p-(2-(5-chloro-2-methoxybenzamido)ethyl)benzenesulfonyl)-3-cyclohexylurea, 5-chloro-N-(2-(4-((((cyclohexylamino)carbonyl)amino)sulfonyl)phenyl)ethyl)-2-methoxybenzamide, DiaBeta, Glibenclamida, Glibenclamide, Glibenclamidum, Glucovance, GlyBURIDE, Micronized, Glyburide-Metformin, Glycron, Glynase, Micronase.
Recent clinical, regulatory, research and industry developments relating to this drug.
Label change: GLYBURIDE AND METFORMIN HYDROCHLORIDE (ANDA206748)
Label change: GLYBURIDE AND METFORMIN HYDROCHLORIDE (ANDA206748)
Oral Glibenclamide in Preterm Infants With Hyperglycaemia (GALOP)
Metabolic Analysis for Treatment Choice in Gestational Diabetes Mellitus
Pharmacological Inhibitors of the NLRP3 Inflammasome.
Approval: GLYBURIDE AND METFORMIN HYDROCHLORIDE (ANDA206748)
Glyburide in Women With Mild Gestational Diabetes: A Randomized Controlled Trial.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Pharmacology & targets
Known molecular targets and mechanisms supported by curated pharmacology databases.
Regulatory timeline
The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.
Indication: Amglidia is indicated for the treatment of neonatal diabetes mellitus, for use in newborns, infants and children. Sulphonylureas like Amglidia have been shown to be effective in… Show full indicationShow less
Amglidia is indicated for the treatment of neonatal diabetes mellitus, for use in newborns, infants and children. Sulphonylureas like Amglidia have been shown to be effective in patients with mutations in the genes coding for the ?-cell ATP-sensitive potassium channel and chromosome 6q24-related transient neonatal diabetes mellitus.
Data from the U.S. Food and Drug Administration (U.S. Food and Drug Administration), public domain (CC0).
Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Glibenclamide in Aneurysmatic Subarachnoid Hemorrhage: A Prospective and Randomized Study
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes2
Journals, researchers & institutions
- Diabetes, obesity & metabolism1
- Frontiers in immunology1
- Obstetrics and gynecology1
- Abbassi-Ghanavati M1
- Casey BM1
- Duryea EL1
- Fleck PR1
- Jin T1
- Kipnes MS1
- Kombe AJK1
- Leveno KJ1
- CAS Center for Excellence in Molecular Cell Science1
- Hefei National Laboratory for Physical Sciences at Microscale1
- The First Affiliated Hospital of USTC1
- University of Texas Southwestern Medical Center1
- University of Vermont College of Medicine1
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials
- Regulatory event sources are credited in the Regulatory Timeline above.